Terapeutiske vacciner er et nyt behandlings-princip ved kastrationsresistent prostatacancer

Sissal Sigmundsdòttir Djurhuus; Klaus Brasso; Kasper Drimer Berg; Peter Iversen; Martin Andreas Røder

Terapeutiske vacciner er et nyt behandlings-princip ved kastrationsresistent prostatacancer

Sissal Sigmundsdòttir Djurhuus, Klaus Brasso, Kasper Drimer Berg, Peter Iversen, Martin Andreas Røder

Institut for Klinisk Medicin

Abstract

Therapeutic vaccines is a novel approach in castration-resistant prostate cancer treatment

Castration-resistant prostate cancer (CRPC) is defined as tumour progression despite castrate levels of serum testosterone. During the past decade a number of new therapies, including chemotherapy and novel endocrine agents have been approved for CRPC treatment. The continued need for new effective drugs in CRPC has led to development of a novel therapeutic approach in CRPC treatment. Therapeutic vaccines activate the immune system to kill prostate cancer cells. This review describes recent pivotal phase 2 and 3 trials of CRPC vaccines and discusses the impact on future CRPC management.

Bidragets oversatte titel	Therapeutic vaccines is a novel approach in castration-resistant prostate cancer treatment
Originalsprog	Dansk
Artikelnummer	22
Tidsskrift	Ugeskrift for Laeger
Vol/bind	177
Udgave nummer	22
Sider (fra-til)	2-7
Antal sider	6
ISSN	0041-5782
Status	Udgivet - 11 maj 2015

FN’s Verdensmål

Dette resultat bidrager til følgende verdensmål

Andre filer og links

http://ugeskriftet.dk/videnskab/terapeutiske-vacciner-er-et-nyt-behandlingsprincip-ved-kastrationsresistent-prostatacancer

Citationsformater

@article{4bceb0342f8c4e29bc3d08c43d3c5f60,

title = "Terapeutiske vacciner er et nyt behandlings-princip ved kastrationsresistent prostatacancer",

abstract = "Therapeutic vaccines is a novel approach in castration-resistant prostate cancer treatmentCastration-resistant prostate cancer (CRPC) is defined as tumour progression despite castrate levels of serum testosterone. During the past decade a number of new therapies, including chemotherapy and novel endocrine agents have been approved for CRPC treatment. The continued need for new effective drugs in CRPC has led to development of a novel therapeutic approach in CRPC treatment. Therapeutic vaccines activate the immune system to kill prostate cancer cells. This review describes recent pivotal phase 2 and 3 trials of CRPC vaccines and discusses the impact on future CRPC management.",

author = "Djurhuus, {Sissal Sigmundsd{\`o}ttir} and Klaus Brasso and Berg, {Kasper Drimer} and Peter Iversen and R{\o}der, {Martin Andreas}",

year = "2015",

month = may,

day = "11",

language = "Dansk",

volume = "177",

pages = "2--7",

journal = "Ugeskrift for Laeger",

issn = "0041-5782",

publisher = "Almindelige Danske Laegeforening",

number = "22",

}

TY - JOUR

T1 - Terapeutiske vacciner er et nyt behandlings-princip ved kastrationsresistent prostatacancer

AU - Djurhuus, Sissal Sigmundsdòttir

AU - Brasso, Klaus

AU - Berg, Kasper Drimer

AU - Iversen, Peter

AU - Røder, Martin Andreas

PY - 2015/5/11

Y1 - 2015/5/11

N2 - Therapeutic vaccines is a novel approach in castration-resistant prostate cancer treatmentCastration-resistant prostate cancer (CRPC) is defined as tumour progression despite castrate levels of serum testosterone. During the past decade a number of new therapies, including chemotherapy and novel endocrine agents have been approved for CRPC treatment. The continued need for new effective drugs in CRPC has led to development of a novel therapeutic approach in CRPC treatment. Therapeutic vaccines activate the immune system to kill prostate cancer cells. This review describes recent pivotal phase 2 and 3 trials of CRPC vaccines and discusses the impact on future CRPC management.

AB - Therapeutic vaccines is a novel approach in castration-resistant prostate cancer treatmentCastration-resistant prostate cancer (CRPC) is defined as tumour progression despite castrate levels of serum testosterone. During the past decade a number of new therapies, including chemotherapy and novel endocrine agents have been approved for CRPC treatment. The continued need for new effective drugs in CRPC has led to development of a novel therapeutic approach in CRPC treatment. Therapeutic vaccines activate the immune system to kill prostate cancer cells. This review describes recent pivotal phase 2 and 3 trials of CRPC vaccines and discusses the impact on future CRPC management.

UR - http://ugeskriftet.dk/videnskab/terapeutiske-vacciner-er-et-nyt-behandlingsprincip-ved-kastrationsresistent-prostatacancer

M3 - Tidsskriftartikel

C2 - 25967247

SN - 0041-5782

VL - 177

SP - 2

EP - 7

JO - Ugeskrift for Laeger

JF - Ugeskrift for Laeger

IS - 22

M1 - 22

ER -

Terapeutiske vacciner er et nyt behandlings-princip ved kastrationsresistent prostatacancer

Abstract

FN’s Verdensmål

Andre filer og links

Fingeraftryk

Citationsformater